BTAI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

166.67K

-54.46%

-0.747

-79.08%

366.67K

+118.26%

-0.643

-57.11%

400.00K

+233.33%

-0.593

-75.78%

Estimates Revision

The market is revising Downward the revenue expectations for BioXcel Therapeutics, Inc. (BTAI) for FY2025, with the revenue forecasts being adjusted by -23.35% over the past three months. During the same period, the stock price has changed by -27.70%.

Revenue Estimates for FY2025

Revise Downward

-23.35%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.12%

In Past 3 Month

Stock Price

Go Down

-27.70%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast BTAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTAI is 10.67 USD with a low forecast of 4.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

1 Sell

Hold

Current: 0.000

Low

4.00

Averages

10.67

High

18.00

Current: 0.000

Low

4.00

Averages

10.67

High

18.00

Mizuho

Neutral

maintain

$2 -> $4

2025-09-12

Reason

Mizuho

Price Target

$2 -> $4

2025-09-12

maintain

Neutral

Reason

Mizuho raised the firm's price target on BioXcel Therapeutics to $4 from $2 and keeps a Neutral rating on the shares. The firm cites the positive Phase 3 SERENITY At-Home study data for BXCL501 for the target doubling. Mizuho's risk-adjusted sales estimate for Igalmi in peak year 2037 is now projected at $390M across three indications, from $325M prior. However, the firm sees continued uncertainty around what type of financing BioXcel will undertake to provide more financial stability.

H.C. Wainwright

Raghuram Selvaraju

Buy

maintain

$8 -> $10

2025-08-15

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$8 -> $10

2025-08-15

maintain

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on BioXcel Therapeutics to $10 from $8 and keeps a Buy rating on the shares following the Q2 report. The firm cites "heightened enthusiasm" for BXCL501's prospects for the target increase. The analyst views the SERENITY readout as low-risk and believes BioXcel could file for the expanded label of BXCL501 by the end of this year and may receive the label extension in the back half of 2026.

Lucid Capital

Buy

maintain

$15

2025-07-15

Reason

Lucid Capital

Price Target

$15

2025-07-15

maintain

Buy

Reason

Lucid Capital reiterates a Buy rating on BioXcel Therapeutics with a $15 price target after the company announced that the U.S. Patent and Trademark Office approved its patent application which covers the use of a single dose of dexmedetomidine in an oromucosal formulation for treating acute agitation in schizophrenia or bipolar patients with QT prolongation under six microseconds. Once officially granted, the patent will be eligible for inclusion in the FDA's Orange Book as the 14th listed patent for Igalmi and is expected to expire on January 12, 2043, pending any patent term adjustments, the analyst tells investors in a research note.

Lucid Capital

NULL

Buy

initiated

$66

2025-06-25

Reason

Lucid Capital

Price Target

$66

2025-06-25

initiated

NULL

Buy

Reason

Lucid Capital initiated coverage of BioXcel Therapeutics with a Buy rating and $66 price target. BioXCel is expanding the use of its approved agitation drug, Igalmi, for at-home use and for Alzheimer's disease, the analyst tells investors in a research note. The firm says there are 7M patients diagnosed with Alzheimer's disease in the U.S. alone and the numbers are expected to double every 20 years with the aging population. It sees blockbuster potential for Igalmi.

H.C. Wainwright

maintain

$3 -> $8

2025-06-23

Reason

H.C. Wainwright

Price Target

$3 -> $8

2025-06-23

maintain

Reason

H.C. Wainwright raised the firm's price target on BioXcel Therapeutics to $8 from $3 and keeps a Buy rating on the shares. The firm cites After the dilution associated with the most recent equity financing in March as well as the impact of the reverse stock split implemented in February for the new target.

Rodman & Renshaw

Elemer Piros

Strong Buy

Initiates

$65

2025-03-19

Reason

Rodman & Renshaw

Elemer Piros

Price Target

$65

2025-03-19

Initiates

Strong Buy

Reason

Rodman & Renshaw initiated coverage of BioXcel Therapeutics with a Buy rating and $65 price target. The firm sees e blockbuster potential and over 2,900% share upside with BioXCel expanding the use of its approved drug, Igalmi, for at-home use and for Alzheimer's disease. The convenience of using the drug at home grows the potential by tenfold, with a market potential of $2B in the U.S., the firm tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for BioXcel Therapeutics Inc (BTAI.O) is -0.41, compared to its 5-year average forward P/E of -2.71. For a more detailed relative valuation and DCF analysis to assess BioXcel Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.71

Current PE

-0.41

Overvalued PE

0.04

Undervalued PE

-5.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.47

Current EV/EBITDA

-1.76

Overvalued EV/EBITDA

-0.35

Undervalued EV/EBITDA

-4.58

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

73.23

Current PS

27.88

Overvalued PS

200.29

Undervalued PS

-53.83

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BTAI News & Events

Events Timeline

No data

News

9.0

01-09Newsfilter

PinnedBioXcel Seeks FDA Approval for At-Home Use of IGALMI® in Agitation Treatment

9.0

01-07NASDAQ.COM

BioXcel Seeks FDA Approval for At-Home Use of IGALMI in Agitation Treatment

1.0

2025-12-03Globenewswire

BioXcel Therapeutics Hosts Virtual Roundtable on Self-Administered Treatment Opportunities

People Also Watch

Frequently Asked Questions

What is BioXcel Therapeutics Inc (BTAI) stock price today?

The current price of BTAI is 2.01 USD — it has increased 0.5 % in the last trading day.

What is BioXcel Therapeutics Inc (BTAI)'s business?

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

What is the price predicton of BTAI Stock?

What is BioXcel Therapeutics Inc (BTAI)'s revenue for the last quarter?

BioXcel Therapeutics Inc revenue for the last quarter amounts to 98.00K USD, decreased -54.21 % YoY.

What is BioXcel Therapeutics Inc (BTAI)'s earnings per share (EPS) for the last quarter?

BioXcel Therapeutics Inc. EPS for the last quarter amounts to -2.18 USD, decreased -57.67 % YoY.

What changes have occurred in the market's expectations for BioXcel Therapeutics Inc (BTAI)'s fundamentals?

How many employees does BioXcel Therapeutics Inc (BTAI). have?

BioXcel Therapeutics Inc (BTAI) has 37 emplpoyees as of January 10 2026.

What is BioXcel Therapeutics Inc (BTAI) market cap?

Today BTAI has the market capitalization of 43.96M USD.